Blog
RSS FeedPosted by Michael Wonder on 18 May 2022
Toward incorporating health-related quality of life as co-primary endpoints in clinical trials: time to achieve clinical important differences and quality of life profiles
16 May 2022 - Besides morbidity and mortality, quality of life is a key outcome of cancer treatments. ...
Posted by Michael Wonder on 11 Apr 2022
The EQ-HWB: overview of the development of a measure of health and wellbeing and key results
8 April 2022 - This article presents an overview of the international development of a new generic measure, the EQ Health ...
Posted by Michael Wonder on 23 Mar 2022
Acceptability of manufacturer proposed utility values for NICE cancer medicine appraisals: analysis of manufacturers’ information sources
21 March 2022 - The NICE method guide for technology appraisals encourages medicine manufacturers to use the EuroQol 5 Dimension in ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 28 Sep 2021
Valuing SF-6Dv2 in Australia using an international protocol
28 September 2021 - The SF-6Dv2 is an updated version of the SF-6D, with improved consistency and dimension descriptors, and value ...
Posted by Michael Wonder on 28 Sep 2021
A review of utility measurement methods used in pharmacoeconomic submissions to HIRA in South Korea: methodological consistency and areas for improvement
28 September 2021 - This study, which was conducted as part of a project for revision of the pharmacoeconomic ...
Posted by Michael Wonder on 14 Feb 2021
Assessment of FDA and EMA approved systemic oncology therapies and clinically meaningful improvements in quality of life
11 February 2021 - Are oncology therapies recently approved by the US FDA and the EMA associated with clinically meaningful improvements ...
Posted by Michael Wonder on 29 Sep 2020
The estimation of health state utility values in rare diseases: overview of existing techniques
25 September 2020 - There are several techniques for estimating health state utility values, each of which presents pros and cons ...
Posted by Michael Wonder on 12 Aug 2020
What is it going to be, TTO or SG? A direct test of the validity of health state valuation
12 August 2020 - It has been suggested that time trade-off yields more accurate health state valuations, because time trade-off ...
Posted by Michael Wonder on 12 May 2020
A comparison of the EQ-5D-3L and EQ-5D-5L
12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...
Posted by Michael Wonder on 17 Mar 2020
Explaining health state utility assessment
17 March 2020 - Health state utilities are used to provide quantitative measures of how strongly a person values a certain ...
Posted by Michael Wonder on 12 Feb 2020
Researchers wanted to study the public’s views of health-related quality of life
12 February 2020 - Applications close on Wednesday 4 March 2020 ...
Posted by Michael Wonder on 28 Oct 2019
NICE to support new valuation study for England for EQ-5D-5L questionnaire
24 October 2019 - Study will measure public’s preference for different health states. ...
Posted by Michael Wonder on 13 Jan 2019
The impact of moving from the EQ-5D-3L to the -5L in NICE technology appraisals
11 January 2019 - The EQ-5D instrument is NICE’s preferred measure of health-related quality of life in adults. ...
Posted by Michael Wonder on 05 Oct 2018
Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology
1 October 2018 - Progression-free survival has become a commonly used outcome to assess the efficacy of new cancer drugs. However, ...